A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 10, 2011, Pages 1757-1760

  Baggstrom, Maria Q ^a   Qi, Yingwei ^b   Koczywas, Marianna ^c   Argiris, Athanassios ^d   Johnson, Elizabeth A ^e   Millward, Michael J ^f   Murphy, Sara C ^g   Erlichman, Charles ^h   Rudin, Charles M ^g   Govindan, Ramaswamy ^a  

^a USA   (United States)

^b MAYO CLINIC   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e MAYO CLINIC   (United States)

^f SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h MAYO CLINIC CANCER CENTER   (United States)

Author keywords

AT 101; Extensive stage small cell lung cancer; Gossypol

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INHIBITOR; BILIRUBIN; GLUCOSE; GOSSYPOL; ISOSORBIDE; MAGNESIUM; PHOSPHATE; POTASSIUM; SODIUM;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 80052995730     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822e2941     Document Type: Article

References (15)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544. (Pubitemid 46630948)
2. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667. (Pubitemid 29075255)
3. Rodriguez E, Lilenbaum RC. Small cell lung cancer: past, present, and future. Curr Oncol Rep 12:327-334.
4. Coutinho EM. Gossypol: a contraceptive for men. Contraception 2002; 65:259-263. (Pubitemid 34518604)
5. Stein RC, Joseph AE, Matlin SA, et al. A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol 1992;30:480-482.
6. Flack MR, Pyle RG, Mullen NM, et al. Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 1993;76:1019-1024. (Pubitemid 23110855)
7. Bushunow P, Reidenberg MM, Wasenko J, et al. Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol 1999;43:79-86. (Pubitemid 29351981)
8. Van Poznak C, Seidman AD, Reidenberg MM, et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat 2001;66:239-248. (Pubitemid 32675026)
9. Choi J, Choi K, Benveniste EN, et al. Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2. Cancer Res 2005; 65:5554-5560. (Pubitemid 40911155)
10. Investigators Brochure, Ascenta Therapeutics, Version 7. 2009.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
13. Heist RS, Fain J, Chinnasami B, et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 5:1637-1643.
14. Paik PK, Rudin CM, Brown A, et al. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 2010;66:1079-1085.
15. Tahir SK, Wass J, Joseph MK, et al. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther 9:545-557.